Copyright Reports & Markets. All rights reserved.

Global Polycythemia Vera Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Polycythemia Vera Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Polycythemia Vera Drug Market Size Growth Rate by Product
      • 1.4.2 Dasatinib
      • 1.4.3 Idelalisib
      • 1.4.4 Givinostat
      • 1.4.5 M-009
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Polycythemia Vera Drug Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Polycythemia Vera Drug Market Size
      • 2.1.1 Global Polycythemia Vera Drug Revenue 2014-2025
      • 2.1.2 Global Polycythemia Vera Drug Sales 2014-2025
    • 2.2 Polycythemia Vera Drug Growth Rate by Regions
      • 2.2.1 Global Polycythemia Vera Drug Sales by Regions
      • 2.2.2 Global Polycythemia Vera Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Polycythemia Vera Drug Sales by Manufacturers
      • 3.1.1 Polycythemia Vera Drug Sales by Manufacturers
      • 3.1.2 Polycythemia Vera Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Polycythemia Vera Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Polycythemia Vera Drug Revenue by Manufacturers
      • 3.2.1 Polycythemia Vera Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Polycythemia Vera Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Polycythemia Vera Drug Price by Manufacturers
    • 3.4 Polycythemia Vera Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Polycythemia Vera Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Polycythemia Vera Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Polycythemia Vera Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Polycythemia Vera Drug Sales by Product
    • 4.2 Global Polycythemia Vera Drug Revenue by Product
    • 4.3 Polycythemia Vera Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Polycythemia Vera Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Polycythemia Vera Drug by Countries
      • 6.1.1 North America Polycythemia Vera Drug Sales by Countries
      • 6.1.2 North America Polycythemia Vera Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Polycythemia Vera Drug by Product
    • 6.3 North America Polycythemia Vera Drug by End User

    7 Europe

    • 7.1 Europe Polycythemia Vera Drug by Countries
      • 7.1.1 Europe Polycythemia Vera Drug Sales by Countries
      • 7.1.2 Europe Polycythemia Vera Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Polycythemia Vera Drug by Product
    • 7.3 Europe Polycythemia Vera Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Polycythemia Vera Drug by Countries
      • 8.1.1 Asia Pacific Polycythemia Vera Drug Sales by Countries
      • 8.1.2 Asia Pacific Polycythemia Vera Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Polycythemia Vera Drug by Product
    • 8.3 Asia Pacific Polycythemia Vera Drug by End User

    9 Central & South America

    • 9.1 Central & South America Polycythemia Vera Drug by Countries
      • 9.1.1 Central & South America Polycythemia Vera Drug Sales by Countries
      • 9.1.2 Central & South America Polycythemia Vera Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Polycythemia Vera Drug by Product
    • 9.3 Central & South America Polycythemia Vera Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Polycythemia Vera Drug by Countries
      • 10.1.1 Middle East and Africa Polycythemia Vera Drug Sales by Countries
      • 10.1.2 Middle East and Africa Polycythemia Vera Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Polycythemia Vera Drug by Product
    • 10.3 Middle East and Africa Polycythemia Vera Drug by End User

    11 Company Profiles

    • 11.1 ANP Technologies, Inc.
      • 11.1.1 ANP Technologies, Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 ANP Technologies, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 ANP Technologies, Inc. Polycythemia Vera Drug Products Offered
      • 11.1.5 ANP Technologies, Inc. Recent Development
    • 11.2 Bristol-Myers Squibb Company
      • 11.2.1 Bristol-Myers Squibb Company Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bristol-Myers Squibb Company Polycythemia Vera Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bristol-Myers Squibb Company Polycythemia Vera Drug Products Offered
      • 11.2.5 Bristol-Myers Squibb Company Recent Development
    • 11.3 F. Hoffmann-La Roche Ltd.
      • 11.3.1 F. Hoffmann-La Roche Ltd. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Products Offered
      • 11.3.5 F. Hoffmann-La Roche Ltd. Recent Development
    • 11.4 Galena Biopharma, Inc.
      • 11.4.1 Galena Biopharma, Inc. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Galena Biopharma, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Galena Biopharma, Inc. Polycythemia Vera Drug Products Offered
      • 11.4.5 Galena Biopharma, Inc. Recent Development
    • 11.5 Gilead Sciences, Inc.
      • 11.5.1 Gilead Sciences, Inc. Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Gilead Sciences, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Gilead Sciences, Inc. Polycythemia Vera Drug Products Offered
      • 11.5.5 Gilead Sciences, Inc. Recent Development
    • 11.6 Italfarmaco S.p.A.
      • 11.6.1 Italfarmaco S.p.A. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Italfarmaco S.p.A. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Italfarmaco S.p.A. Polycythemia Vera Drug Products Offered
      • 11.6.5 Italfarmaco S.p.A. Recent Development
    • 11.7 Karus Therapeutics Limited
      • 11.7.1 Karus Therapeutics Limited Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Karus Therapeutics Limited Polycythemia Vera Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Karus Therapeutics Limited Polycythemia Vera Drug Products Offered
      • 11.7.5 Karus Therapeutics Limited Recent Development
    • 11.8 miRagen Therapeutics, Inc.
      • 11.8.1 miRagen Therapeutics, Inc. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 miRagen Therapeutics, Inc. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 miRagen Therapeutics, Inc. Polycythemia Vera Drug Products Offered
      • 11.8.5 miRagen Therapeutics, Inc. Recent Development
    • 11.9 Nerviano Medical Sciences S.r.l.
      • 11.9.1 Nerviano Medical Sciences S.r.l. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Products Offered
      • 11.9.5 Nerviano Medical Sciences S.r.l. Recent Development
    • 11.10 Novartis AG
      • 11.10.1 Novartis AG Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Novartis AG Polycythemia Vera Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Novartis AG Polycythemia Vera Drug Products Offered
      • 11.10.5 Novartis AG Recent Development
    • 11.11 PharmaEssentia Corporation
    • 11.12 Teva Pharmaceutical Industries Ltd.

    12 Future Forecast

    • 12.1 Polycythemia Vera Drug Market Forecast by Regions
      • 12.1.1 Global Polycythemia Vera Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Polycythemia Vera Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Polycythemia Vera Drug Market Forecast by Product
      • 12.2.1 Global Polycythemia Vera Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Polycythemia Vera Drug Revenue Forecast by Product 2019-2025
    • 12.3 Polycythemia Vera Drug Market Forecast by End User
    • 12.4 North America Polycythemia Vera Drug Forecast
    • 12.5 Europe Polycythemia Vera Drug Forecast
    • 12.6 Asia Pacific Polycythemia Vera Drug Forecast
    • 12.7 Central & South America Polycythemia Vera Drug Forecast
    • 12.8 Middle East and Africa Polycythemia Vera Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Polycythemia Vera Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Polycythemia Vera Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Polycythemia Vera Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Polycythemia Vera Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Polycythemia Vera Drug in these regions.
      This research report categorizes the global Polycythemia Vera Drug market by top players/brands, region, type and end user. This report also studies the global Polycythemia Vera Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      ANP Technologies, Inc.
      Bristol-Myers Squibb Company
      F. Hoffmann-La Roche Ltd.
      Galena Biopharma, Inc.
      Gilead Sciences, Inc.
      Italfarmaco S.p.A.
      Karus Therapeutics Limited
      miRagen Therapeutics, Inc.
      Nerviano Medical Sciences S.r.l.
      Novartis AG
      PharmaEssentia Corporation
      Teva Pharmaceutical Industries Ltd.

      Market size by Product
      Dasatinib
      Idelalisib
      Givinostat
      M-009
      Others
      Market size by End User
      Clinic
      Hospital
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Polycythemia Vera Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Polycythemia Vera Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Polycythemia Vera Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Polycythemia Vera Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Polycythemia Vera Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Polycythemia Vera Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now